Get the Stockscreener App
372.74
1.15%
-4.38
Overview
News
Price History
Option Chain
Financials
Why SYK Down?
Discussions
Forecast
Stock Split
Dividend History
Stryker Corp stock is traded at $372.74, with a volume of 603.26K.
It is down -1.15% in the last 24 hours and down -5.44% over the past month.
Stryker designs, manufactures, and markets an array of medical equipment, instruments, consumable supplies, and implantable devices. The product portfolio includes hip and knee replacements, extremities, endoscopy systems, operating room equipment, embolic coils, hospital beds and gurneys, and orthopedic robotics. Stryker remains one of the three largest competitors in reconstructive orthopedic implants and holds the leadership position in operating room equipment. Roughly one fourth of Stryker's total revenue currently comes from outside the United States.
See More
Previous Close:
$377.12
Open:
$376.44
24h Volume:
603.26K
Relative Volume:
0.41
Market Cap:
$146.09B
Revenue:
$23.22B
Net Income/Loss:
$2.86B
P/E Ratio:
50.37
EPS:
7.4
Net Cash Flow:
$3.58B
1W Performance:
-3.19%
1M Performance:
-5.44%
6M Performance:
+0.53%
1Y Performance:
+8.15%
1-Day Range:
$371.90
$376.99
1-Week Range:
$371.90
$385.42
52-Week Range:
$314.93
$406.19
Stryker Corp Stock (SYK) Company Profile
Name
Stryker Corp
Sector
Industry
Phone
(269) 385-2600
Address
1941 STRYKER WAY, PORTAGE, MI
Compare SYK with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SYK
Stryker Corp
|
372.74 | 146.09B | 23.22B | 2.86B | 3.58B | 7.40 |
|
ABT
Abbott Laboratories
|
132.72 | 232.09B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
101.79 | 148.00B | 17.55B | 2.03B | 2.72B | 1.37 |
|
MDT
Medtronic Plc
|
86.30 | 112.11B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
73.29 | 44.79B | 5.54B | 4.18B | 623.10M | 7.00 |
Stryker Corp Stock (SYK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-26-25 | Resumed | Citigroup | Buy |
| Dec-02-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-10-24 | Initiated | Wolfe Research | Outperform |
| May-30-24 | Initiated | Goldman | Neutral |
| May-22-24 | Upgrade | Needham | Hold → Buy |
| Jan-31-24 | Upgrade | Canaccord Genuity | Hold → Buy |
| Oct-20-23 | Initiated | ROTH MKM | Buy |
| Sep-05-23 | Upgrade | BofA Securities | Neutral → Buy |
| Mar-29-23 | Initiated | UBS | Neutral |
| Jan-25-23 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Jan-09-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-01-22 | Downgrade | Canaccord Genuity | Buy → Hold |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Jul-28-22 | Upgrade | Edward Jones | Hold → Buy |
| Jul-21-22 | Downgrade | Deutsche Bank | Buy → Hold |
| Jul-11-22 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-13-22 | Initiated | Truist | Hold |
| Mar-16-22 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Mar-15-22 | Resumed | Evercore ISI | Outperform |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Jan-07-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-04-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-10-21 | Initiated | RBC Capital Mkts | Sector Perform |
| Dec-07-21 | Initiated | Loop Capital | Buy |
| Sep-14-21 | Resumed | Raymond James | Mkt Perform |
| Jul-28-21 | Upgrade | Northland Capital | Market Perform → Outperform |
| Jun-01-21 | Upgrade | Evercore ISI | In-line → Outperform |
| May-25-21 | Initiated | Barclays | Underweight |
| Oct-06-20 | Initiated | Northland Capital | Market Perform |
| Sep-11-20 | Initiated | Wolfe Research | Peer Perform |
| Apr-13-20 | Downgrade | Barclays | Equal Weight → Underweight |
| Apr-01-20 | Downgrade | Goldman | Buy → Sell |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Buy |
| Jan-08-20 | Initiated | SunTrust | Hold |
| Jan-07-20 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Jan-07-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-30-19 | Reiterated | BTIG Research | Buy |
| Nov-05-19 | Downgrade | Barclays | Overweight → Equal Weight |
| Oct-30-19 | Reiterated | BofA/Merrill | Buy |
| Jul-02-19 | Downgrade | Evercore ISI | Outperform → In-line |
| Jan-30-19 | Reiterated | Canaccord Genuity | Buy |
| Jan-03-19 | Initiated | Deutsche Bank | Buy |
| Jan-02-19 | Upgrade | Evercore ISI | In-line → Outperform |
| Oct-16-18 | Initiated | Barclays | Overweight |
| Aug-16-18 | Initiated | BTIG Research | Buy |
| Jun-27-18 | Initiated | Bernstein | Mkt Perform |
| Apr-27-18 | Reiterated | Stifel | Buy |
View All
Stryker Corp Stock (SYK) Latest News
Stryker Beats Sales Worker’s Military, Medical Leave Bias Claims - Bloomberg Law News
Stryker (SYK): Buy, Sell, or Hold Post Q1 Earnings? - Yahoo Finance
Stryker’s SWOT analysis: medical tech giant eyes growth amid challenges By Investing.com - Investing.com Canada
Stryker’s SWOT analysis: medical tech giant eyes growth amid challenges - Investing.com
These are West Michigan’s highest-paid CEOs at publicly traded companies - Crain's Grand Rapids Business
The Zacks Analyst Blog Highlights Mastercard, Verizon Communications, Stryker, Espey Mfg. & Electronics and Comstock Holding - Yahoo Finance
Top Analyst Reports for Mastercard, Verizon & Stryker - MSN
Is Stryker Stock Underperforming the Nasdaq? - MSN
Global AI in Remote Patient Monitoring Market to Cross USD 13 Billion by 2032 | DelveInsight - GlobeNewswire Inc.
Surgical Booms Market Is Booming WorldwideStryker - openPR.com
Is Stryker Stock Underperforming The Nasdaq? - Barchart.com
Pressure Relief Devises Industry Overview: Innovations & Key - openPR.com
Barclays maintains Stryker stock Overweight rating, $443 target By Investing.com - Investing.com South Africa
Barclays maintains Stryker stock Overweight rating, $443 target - Investing.com
Here's How Much $1000 Invested In Stryker 20 Years Ago Would Be Worth Today - Benzinga
Stryker tops list of West Michigan’s largest publicly traded companies - Crain's Grand Rapids Business
Jim Cramer on Stryker Corporation (SYK): “I Don’t Like It Enough” - Insider Monkey
Jim Cramer Had These 21 Stocks on His Radar - Insider Monkey
Stryker’s SWOT analysis: stock poised for growth amid strategic moves - Investing.com
Stryker corp VP sells shares worth $211,369 - Investing.com Australia
Stryker corp’s chief accounting officer sells $211,369 in shares By Investing.com - Investing.com South Africa
Stryker corp VP sells shares worth $211,369 By Investing.com - Investing.com Nigeria
Stryker corp’s chief accounting officer sells $211,369 in shares - Investing.com Australia
Stryker Hits Treace With Patent Suit Over Surgical Foot-Implants - Bloomberg Law News
Stryker Corporation: Is Its Tuck-in Acquisition Strategy to Ensure Market Leadership In The Med-Tech Landscape? - Smartkarma
Citigroup Raises Price Target for Stryker (SYK) to $455 | SYK Stock News - GuruFocus
Stryker wins FDA clearance for minimally invasive back pain treatment - Yahoo Finance
Stryker (SYK) Price Target Raised by Citi to $455 | SYK Stock Ne - GuruFocus
Stryker (NYSE:SYK) Expands Pain Therapy With FDA Clearance For OptaBlate BVN System - Yahoo Finance
USITC to investigate Fiagon after Stryker medical device infringement claims - MLex
SYK Stock Likely to Rise Following FDA Clearance for OptaBlate System - Yahoo Finance
Stryker Receives FDA Clearance For OptaBlate System Aimed At Low Back Pain Relief: Retail’s Yet To React - Investing.com India
Stryker (SYK) Gains FDA Clearance for OptaBlate System - GuruFocus
Stryker (SYK) Secures FDA Clearance for OptaBlate Nerve Ablation System | SYK Stock News - GuruFocus
Stryker’s new system aims at chronic back pain relief - Investing.com
Stryker receives FDA clearance for OptaBlate® BVN Basivertebral Nerve Ablation System – Company Announcement - Financial Times
Stryker Stock: Analyst Estimates & Ratings - Barchart.com
Stryker’s CEO Steps Down Abruptly - Medical Product Outsourcing
Stryker Inks Deal to Buy One of Its Suppliers Stryker Corp. will pay $150 million for Gaymar Indu - Medical Product Outsourcing
Boston Sci Closes Division Sale to Stryker Corp. On Jan. 3, Boston Scientific Corp. completed the - Medical Product Outsourcing
Stryker Moves to Settle DOJ Probe - Medical Product Outsourcing
Stryker’s Bone Growth Division Sold to Olympus Corp. Stryker Corp. has inked a deal to sell - Medical Product Outsourcing
Insulet Adds Stryker Executive to Board - Medical Product Outsourcing
Former Stryker CEO Receives Lifetime Achievement Award from AdvaMed - Medical Product Outsourcing
Stryker Settles for $80 Million in Unapproved Device Sales Case - Medical Product Outsourcing
Stryker Snaps Up Concentric for $135M - Medical Product Outsourcing
First-Quarter Sales Strong at Stryker Corp. - Medical Product Outsourcing
Stryker: We’re Not Buying Smith & Nephew … Yet, But We’re Interested - Medical Product Outsourcing
SYK Q1 Earnings Call: Stryker Delivers Revenue Beat, Cites International Growth and Tariff Headwinds - Yahoo Finance
Top Executive Sells Stryker Shares in Major Transaction - TipRanks
Stryker Corp Stock (SYK) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.21%
1.92%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):